Program
bizrolertinib
Also written as “ZN-A-1041”, “RO7771950” and “ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b”.
Its studies are mostly in Brain Neoplasms · Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 42 open or running | phase 3since Feb 10, 2026 | Oct 17, 2022 | Aug 31, 2027phase 2 · NCT05593094 |
| Suzhou Zanrong Pharma | 10 open or running | phase 1since Jul 10, 2020 | Jul 10, 2020 | none ahead |
- Named in Hoffmann-La Roche’s own pipeline as
RG6596 bizrolertinib
, phase 2, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 10, 2020First study: phase 1 study in Brain NeoplasmsNew to Suzhou Zanrong PharmaSuzhou Zanrong Pharma · NCT04487236 · 61 enrolled · China
- Oct 17, 2022Hoffmann-La Roche’s first study: phase 2 study in Brain NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT05593094 · 210 enrolled · United States, Australia, France and more
- Jun 26, 2025Phase 1 study in Healthy ParticipantsHoffmann-La Roche · NCT07051993 · 18 enrolled · United Kingdom
- Nov 20, 2025Phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT07329972 · 24 enrolled · United States
- Feb 10, 2026Phase 3 study in HER2-positive Breast CancerPhase 3 reachedHoffmann-La Roche · NCT07413939 · 650 planned · United States, Argentina, Australia and more
Ahead
- Aug 31, 2027Primary completion: phase 2 study in Brain NeoplasmsHoffmann-La Roche · NCT05593094
- May 1, 2029Primary completion: phase 3 study in HER2-positive Breast CancerHoffmann-La Roche · NCT07413939
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon oral administration, bizrolertinib selectively binds to and inhibits the activity of HER2. This prevents HER2-mediated signa…”NCIt, read by Claude
“An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07413939HER2-positive Breast Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Hoffmann-La Roche | May 1, 2029 | 650 |
| NCT07329972Healthy Volunteers · United States | 1 | Completed | Hoffmann-La Roche | Dec 14, 2025 | 24 |
| NCT07051993Healthy Participants · United Kingdom | 1 | Completed | Hoffmann-La Roche | Jul 12, 2025 | 18 |
| NCT05593094Brain Neoplasms · United States, Australia, France and more | 2 | Active, not recruiting | Hoffmann-La Roche | Aug 31, 2027 | 210 |
| NCT04487236Brain Neoplasms · China | 1 | Completed | Suzhou Zanrong Pharma | Apr 16, 2024 | 61 |
How it is read
Names in the registry
- “ZN-A-1041”, 2 entries
- “RO7771950”, 1 entry
- “ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b”, 1 entry
- “ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b”, 1 entry
- “ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b”, 1 entry
Conditions, from the studies’ own filings
- Brain Neoplasms, 2 studies
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.